These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38644693)
1. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Szuber N; Orazi A; Tefferi A Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693 [TBL] [Abstract][Full Text] [Related]
2. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Patnaik MM; Tefferi A Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682 [TBL] [Abstract][Full Text] [Related]
3. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia. Qian Y; Chen Y; Li X Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276 [TBL] [Abstract][Full Text] [Related]
4. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies. Kim SY; Song IC; Kim J; Kwon GC Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470 [TBL] [Abstract][Full Text] [Related]
9. Atypical CML: diagnosis and treatment. Breccia M Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919 [TBL] [Abstract][Full Text] [Related]
10. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671 [TBL] [Abstract][Full Text] [Related]
11. Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management. Szuber N; Elliott M; Tefferi A Am J Hematol; 2022 Apr; 97(4):491-505. PubMed ID: 35089603 [TBL] [Abstract][Full Text] [Related]
12. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042 [TBL] [Abstract][Full Text] [Related]